Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Sequencing › Veracyte Prices $51.3M Public Offering

Veracyte Prices $51.3M Public Offering

Jul 26, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Veracyte late on Wednesday priced its previously announced public offering of 5 million shares of its common stock at $10.25 per share to raise an anticipated $51.3 million in gross proceeds.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Nov
10
Featured Webinar

IVDR in Light of the COVID Pandemic: The Near Future of In Vitro Diagnostic Testing

Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

What's Popular?

In Molecular Diagnostics

  1. Danaher Q3 Revenues Up 35 Percent

  2. COVID-19 Testing Plays Into Abbott's Long-Term Diagnostic Strategy

    Premium

  3. BioMérieux Q3 Revenues Increase 21 Percent

  4. Invitae, Pacific Biosciences Collaborate on NGS-Based Pediatric Epilepsy Testing

  5. Abbott Q3 Diagnostics Revenues Increase 38 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.